Resource Library
|
|
|
|||||||||
|
Powered by:
This information is provided by an independent source. Merck & Co., Inc. is not responsible for this content. Please discuss any and all treatment options with your healthcare professional. The manufacturer of a product generally has the most complete information about that product.
Guillain-Barre syndromeDefinitionGuillain-Barre syndrome is a serious disorder that occurs when the body's defense (immune) system mistakenly attacks part of the nervous system. This leads to nerve inflammation that causes muscle weakness. Alternative NamesLandry-Guillain-Barre syndrome; GBS; Acute idiopathic polyneuritis; Infectious polyneuritis; Acute inflammatory polyneuropathy CausesGuillain-Barre syndrome is an autoimmune disorder (the body's immune system attacks itself). Exactly what triggers Guillain-Barre syndrome is unknown. The syndrome may occur at any age, but is most common in people of both sexes between ages 30 and 50. It often follows a minor infection, usually a lung infection or gastrointestinal infection. Usually, signs of the original infection have disappeared before the symptoms of Guillain-Barre begin. Guillain-Barre syndrome causes inflammation that damages parts of nerves. This nerve damage causes tingling, muscle weakness, and paralysis. The inflammation usually affects the nerve's covering (myelin sheath). Such damage is called demyelination. Demyelination slows nerve signaling. Damage to other parts of the nerve can cause the nerve to stop working. Guillain-Barre syndrome may occur along with viral infections such as:
It may also occur with other medical conditions such as systemic lupus erythematosus or Hodgkin's disease. Some people may get Guillain-Barre syndrome after a bacterial infection or certain vaccinations (such as rabies and swine flu). A similar syndrome may occur after surgery, or when critically ill. SymptomsSymptoms of Guillain-Barre can get worse very quickly. It may take only a few hours to reach the most severe symptoms, but weakness increasing over several days is also common. Muscle weakness or the loss of muscle function (paralysis) affects both sides of the body. In most cases, the muscle weakness starts in the legs and then spreads to the arms. This is called ascending paralysis. Patients may notice tingling, foot or hand pain, and clumsiness. If the inflammation affects the nerves to the diaphragm, and there is weakness in those muscles, the person may need breathing assistance. Typical symptoms include:
Additional symptoms may include:
Emergency symptoms (seek immediate medical help):
Exams and TestsA history of increasing muscle weakness and paralysis may be a sign of Guillain-Barre syndrome, especially if there was a recent illness. A medical exam may show muscle weakness and problems with involuntary (autonomic) body functions such as blood pressure and heart rate. The examination may also show that reflexes, such as the "knee jerk," are decreased or missing. There may be signs of decreased breathing (caused by paralysis of the breathing muscles). The following tests may be ordered:
TreatmentThis version of the Encyclopedia has no treatment information. Please discuss any and all treatment options for your condition with your healthcare professional. Support GroupsGuillain-Barre Syndrome Foundation International - www.gbsfi.com Outlook (Prognosis)Recovery can take weeks or years. Most people survive and recover completely. According to the National Institute of Neurological Disorders and Stroke, about 30% of patients still have some weakness after 3 years. Mild weakness may persist for some people. A patient's outcome is most likely to be very good when the symptoms go away within 3 weeks after they first started. Possible Complications
When to Contact a Medical ProfessionalSeek immediate medical help if you have any of the following symptoms:
ReferencesHughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2009;(1):CD002063. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61(6):736-740. Sharar E. Current therapeutic options in severe Guillain-Barre syndrome. Clin Neuropharmacol. 2006;29(1):45-51. Roos KL. Viral infections. In: Goetz CG, ed. Textbook of Clinical Neurology. 3rd ed. Philadelphia, PA: Saunders Elsevier; 2007:chap 41.
Review Date:
6/24/2009 Reviewed By: Linda Vorvick, MD, Medical Director, MEDEX Northwest Division of Physician Assistant Studies, University of Washington School of Medicine; Daniel B. Hoch, PhD, MD, Assistant Professor of Neurology, Harvard Medical School, Department of Neurology, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc. The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-
A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
|
||||||||||









